ClinicalTrials.gg
CompletedNCT01026142Updated Aug 14, 2018Results posted

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

A Phase 3 interventional study of Capecitabine and Capecitabine in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 190 sites in 23 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-14.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
452
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 104 studies testing pertuzumab in Breast Neoplasms — 26 open to participants now, 45 under way, 7 of them phase 3. pertuzumab · Breast Neoplasms.

Enrollment
15th of 104
452 · median 100
Started
2010
with 2 others
Phase 3
23 of 104
2 open now
Registered
6th of 104
by date
Lead sponsor
20 of 104
Hoffmann-La Roche

Among the 104 studies testing pertuzumab in Breast Neoplasms, this one is the 15th largest by enrollment, is one of 3 that started in 2010, is one of 23 in phase 3, and was the 6th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

26 of the 104 studies testing pertuzumab in Breast Neoplasms are open now, in 11 countries. Recruiting first, the newest first:

21 more — sign in →

By country, each count listing its studies:

All 26 open studies →

About pertuzumab

pertuzumab: first FDA approval 2012 (PERJETA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies testing pertuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This randomized, two-arm study evaluated the efficacy and safety of a combination of trastuzumab and capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. The study population consisted of female patients, whose disease had progressed during or following previous trastuzumab therapy for metastatic disease. All patients in Arm A and Arm B received trastuzumab (8 mg/kg iv as loading dose and then 6 mg/kg iv every 3 weeks thereafter) and capecitabine oral twice daily for 14 days every 3 weeks (1250 mg/m2 twice daily in Arm A and 1000 mg/m2 twice daily in Arm B). In addition, patients in Arm B received pertuzumab (840 mg iv as loading dose and then 420 mg iv thereafter) every 3 weeks. Study treatment continued until disease progression or unacceptable toxicity.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult female patients >/=18 years of age
  • positive breast cancer
  • (ECOG) performance status 0 or 1
  • Disease progression during or following trastuzumab-based therapy for metastatic breast cancer (trastuzumab must have been part of the last prior treatment regimen)
  • Prior treatment with taxane-containing regimen
  • (LVEF) >/=50 percent
  • For women of agreement to use highly effective non-hormonal form of or two effective forms of non-hormonal contraception by patient and/or partner. Contraception must continue for duration of study treatment and for at least 6 months after last dose of study drug treatment

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with pertuzumab or capecitabine
  • Concurrent treatment with other experimental drug
  • Concurrent immunotherapy or anticancer hormonal therapy
  • Serious concurrent disease (e.g. active infection, uncontrolled hypertension, cardiovascular disease)
  • Central nervous system (CNS) , which are not well controlled
  • History of exposure to anthracycline cumulative dose equivalent to 360mg/m2
  • History of congestive heart failure of any criteria, or serious cardiac arrhythmia requiring treatment
  • History of myocardial infarction within 6 months prior to randomization
  • History of decline to below 50% during or after prior trastuzumab therapy or other cardiac toxicity during previous trastuzumab treatment that necessitated discontinuation of trastuzumab
  • History of another cancer which could affect compliance or result interpretation
  • Inadequate organ function
  • Pregnant or breastfeeding women
  • \< 12 weeks
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
452 participants (actual)

Study arms

  • Active comparator
    A: Capecitabine + Trastuzumab

    Drug: Capecitabine · Drug: Trastuzumab

  • Experimental
    B: Capecitabine + Trastuzumab + Pertuzumab

    Drug: Capecitabine · Drug: Pertuzumab · Drug: Trastuzumab

Interventions

  • 1000 mg/m2 po twice daily for 14 days every 3 weeks

    Also known as: Xeloda

  • 1250 mg/m2 po twice daily for 14 days every 3 weeks

    Also known as: Xeloda

  • 840 mg iv loading, then 420 mg iv every 3 weeks

    Also known as: Perjeta

  • 8 mg/kg iv loading, then 6 mg/kg iv every 3 weeks

    Also known as: Herceptin

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (Independent Assessment)

    Progression Free Survival (PFS) was defined as the time from randomization to first documented disease progression (PD), as determined by an Independent Review Facility (IRF) using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0, or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. IRF review of tumor assessment ceased after the primary PFS analysis. The primary endpoint was analyzed after approximately 337 IRF-assessed PFS events were observed.

    Time frame: Tumor assessments every 9 weeks from randomization until Week 27, then every 12 weeks thereafter, until IRF-determined PD, initiation of alternative anticancer medication, or death (up to 5.5 years).

Secondary outcomes

  1. Overall Survival (OS)

    Overall Survival (OS) was defined as the time from the date of randomization to the date of death from any cause. The results of the final OS analysis are presented here. Participants who were alive or lost to follow-up at the time of the analysis were censored at the last known alive date. Participants with no postbaseline information were censored at the time of randomization plus 1 day. Prior to the final data analysis cut-off, it was ensured that all participants who were in survival follow-up had been contacted as recently as possible within the last 3 months to confirm current survival status.

    Time frame: From randomization until death from any cause (up to 7.5 years).

  2. Overall Survival (OS) Rate Based on a 2-year Truncated Analysis

    The Overall Survival (OS) 2-year truncated analysis is the Kaplan-Meier estimate of the percentage of participants who were surviving at 2 years. OS is defined as the time from the date of randomization to the date of death from any cause, with censoring of all events and follow-up beyond the end of the second year.

    Time frame: From randomization until death from any cause (up to 2 years)

  3. Investigator Assessment Progression-Free Survival (PFS)

    Investigator Assessment Progression-Free Survival (PFS) was defined as the time from randomization to the first documented progressive disease, as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) v1.0, or death from any cause, whichever occurred first. PD is defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.

    Time frame: Tumor assessments every 9 weeks from randomization until Week 27, then every 12 weeks thereafter, until IRF-determined PD, initiation of alternative anticancer medication, or death (up to 7.5 years).

  4. Time to Progression (TTP) Based Upon Independent Review Facility (IRF) Assessment

    Time to Progression (TTP) was defined as time between randomization and the first occurrence of progressive disease (PD), based on IRF assessment.

    Time frame: Tumor assessments every 9 weeks from randomization until Week 27, then every 12 weeks thereafter, until IRF-determined PD, initiation of alternative anticancer medication, or death (up to 5.5 years).

  5. Time to Treatment Failure (TTF) Based Upon Independent Review Facility (IRF) Assessment

    Time to Treatment Failure (TTF) was defined as time between randomization and date of disease progression based on independent review, death, or withdrawal of treatment due to adverse events, withdrawn informed consent, refusal of treatment/failure to cooperate, or failure to return, whichever occurred first.

    Time frame: Tumor assessments every 9 weeks from randomization until Week 27, then every 12 weeks thereafter, until IRF-determined PD, initiation of alternative anticancer medication, or death (up to 5.5 years).

  6. Overall Objective Response Rate (ORR)

    Overall Objective Response Rate is based upon investigator and IRF assessments. Objective Response Rate (ORR) was defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) among those who had measurable disease at baseline. CR was defined as the disappearance of all target lesions. PR was defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.

    Time frame: Tumor assessments every 9 weeks from randomization until Week 27, then every 12 weeks thereafter, until IRF-determined PD, initiation of alternative anticancer medication, or death (up to 5.5 years).

  7. Clinical Benefit Rate (CBR)

    Clinical Benefit Rate is based upon Independent Review Facility (IRF) assessments; defined as the percentage of participants a complete response (CR), partial response (PR), or stable disease for at least 8 cycles or 6 months.

    Time frame: Tumor assessments every 9 weeks from randomization until Week 27, then every 12 weeks thereafter, until IRF-determined PD, initiation of alternative anticancer medication, or death (up to 5.5 years).

  8. Duration of Objective Response

    Duration of Objective Response was defined for the subpopulation of responders as time from first Independent Review Facility (IRF)-assessed complete response (CR) or partial response (PR) to subsequent first documented, IRF-confirmed evidence of disease progression. Only participants with an objective response were included in the analysis of duration of objective response.

    Time frame: Tumor assessments every 9 weeks from randomization until Week 27, then every 12 weeks thereafter, until IRF-determined PD, initiation of alternative anticancer medication, or death (up to 5.5 years).

07

Results

Posted Oct 13, 2016

Participant flow

452 participants were randomized to one of two treatment arms: trastuzumab and capecitabine (Arm A, 224 participants) or pertuzumab with trastuzumab and capecitabine (Arm B, 228 participants). Of participants randomized to Arm A: trastuzumab and capecitabine, 6 participants did not receive study treatment.

Participant flow — Overall Study
MilestoneA: Capecitabine + TrastuzumabB: Capecitabine + Trastuzumab + Pertuzumab
Started224228
Completed5265
Not completed172163
Withdrew: Death136134
Withdrew: Withdrew consent or lost to follow-up3629

Outcome measures

PrimaryProgression Free Survival (Independent Assessment)

Progression Free Survival (PFS) was defined as the time from randomization to first documented disease progression (PD), as determined by an Independent Review Facility (IRF) using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0, or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. IRF review of tumor assessment ceased after the primary PFS analysis. The primary endpoint was analyzed after approximately 337 IRF-assessed PFS events were observed.

Time frame:
Tumor assessments every 9 weeks from randomization until Week 27, then every 12 weeks thereafter, until IRF-determined PD, initiation of alternative anticancer medication, or death (up to 5.5 years).
Reported as:
Median · months
Progression Free Survival (Independent Assessment)
monthsA: Capecitabine + TrastuzumabB: Capecitabine + Trastuzumab + Pertuzumab
Progression Free Survival (Independent Assessment)9.0 (8 to 10)11.1 (9 to 13)
Statistical analysis
  • A: Capecitabine + Trastuzumab vs B: Capecitabine + Trastuzumab + Pertuzumab · Log Rank · p = 0.0731 (The primary endpoint, IRF-assessed PFS, is tested at a two-sided 5% significance level.) · Hazard ratio (hr): 0.82 · 95% CI 0.65 to 1.02The stratified Cox proportional hazard model will be used to estimate the HR between the two treatment arms and its 95% CI.
SecondaryOverall Survival (OS)

Overall Survival (OS) was defined as the time from the date of randomization to the date of death from any cause. The results of the final OS analysis are presented here. Participants who were alive or lost to follow-up at the time of the analysis were censored at the last known alive date. Participants with no postbaseline information were censored at the time of randomization plus 1 day. Prior to the final data analysis cut-off, it was ensured that all participants who were in survival follow-up had been contacted as recently as possible within the last 3 months to confirm current survival status.

Time frame:
From randomization until death from any cause (up to 7.5 years).
Reported as:
Median · Months
Overall Survival (OS)
MonthsA: Capecitabine + TrastuzumabB: Capecitabine + Trastuzumab + Pertuzumab
Overall Survival (OS)28.1 (22 to 35)37.2 (33 to 42)
SecondaryOverall Survival (OS) Rate Based on a 2-year Truncated Analysis

The Overall Survival (OS) 2-year truncated analysis is the Kaplan-Meier estimate of the percentage of participants who were surviving at 2 years. OS is defined as the time from the date of randomization to the date of death from any cause, with censoring of all events and follow-up beyond the end of the second year.

Time frame:
From randomization until death from any cause (up to 2 years)
Reported as:
Number · Percentage of participants
Overall Survival (OS) Rate Based on a 2-year Truncated Analysis
Percentage of participantsA: Capecitabine + TrastuzumabB: Capecitabine + Trastuzumab + Pertuzumab
Overall Survival (OS) Rate Based on a 2-year Truncated Analysis55.0 (48.07 to 61.85)74.9 (69.05 to 80.68)
SecondaryInvestigator Assessment Progression-Free Survival (PFS)

Investigator Assessment Progression-Free Survival (PFS) was defined as the time from randomization to the first documented progressive disease, as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) v1.0, or death from any cause, whichever occurred first. PD is defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.

Time frame:
Tumor assessments every 9 weeks from randomization until Week 27, then every 12 weeks thereafter, until IRF-determined PD, initiation of alternative anticancer medication, or death (up to 7.5 years).
Reported as:
Median · Months
Investigator Assessment Progression-Free Survival (PFS)
MonthsA: Capecitabine + TrastuzumabB: Capecitabine + Trastuzumab + Pertuzumab
Investigator Assessment Progression-Free Survival (PFS)9.0 (8 to 12)11.8 (9 to 14)
SecondaryTime to Progression (TTP) Based Upon Independent Review Facility (IRF) Assessment

Time to Progression (TTP) was defined as time between randomization and the first occurrence of progressive disease (PD), based on IRF assessment.

Time frame:
Tumor assessments every 9 weeks from randomization until Week 27, then every 12 weeks thereafter, until IRF-determined PD, initiation of alternative anticancer medication, or death (up to 5.5 years).
Reported as:
Median · Weeks
Time to Progression (TTP) Based Upon Independent Review Facility (IRF) Assessment
WeeksA: Capecitabine + TrastuzumabB: Capecitabine + Trastuzumab + Pertuzumab
Time to Progression (TTP) Based Upon Independent Review Facility (IRF) Assessment39.0 (35 to 44)50.6 (39 to 62)
SecondaryTime to Treatment Failure (TTF) Based Upon Independent Review Facility (IRF) Assessment

Time to Treatment Failure (TTF) was defined as time between randomization and date of disease progression based on independent review, death, or withdrawal of treatment due to adverse events, withdrawn informed consent, refusal of treatment/failure to cooperate, or failure to return, whichever occurred first.

Time frame:
Tumor assessments every 9 weeks from randomization until Week 27, then every 12 weeks thereafter, until IRF-determined PD, initiation of alternative anticancer medication, or death (up to 5.5 years).
Reported as:
Median · Weeks
Time to Treatment Failure (TTF) Based Upon Independent Review Facility (IRF) Assessment
WeeksA: Capecitabine + TrastuzumabB: Capecitabine + Trastuzumab + Pertuzumab
Time to Treatment Failure (TTF) Based Upon Independent Review Facility (IRF) Assessment39.0 (34 to 44)50.9 (39 to 62)
SecondaryOverall Objective Response Rate (ORR)

Overall Objective Response Rate is based upon investigator and IRF assessments. Objective Response Rate (ORR) was defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) among those who had measurable disease at baseline. CR was defined as the disappearance of all target lesions. PR was defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.

Time frame:
Tumor assessments every 9 weeks from randomization until Week 27, then every 12 weeks thereafter, until IRF-determined PD, initiation of alternative anticancer medication, or death (up to 5.5 years).
Reported as:
Number · Percentage of participants
Overall Objective Response Rate (ORR)
Percentage of participantsA: Capecitabine + TrastuzumabB: Capecitabine + Trastuzumab + Pertuzumab
Complete Response (CR) - IRF Assessment01.8
Partial Response (PR) - IRF assessment32.938.7
Complete Response (CR) - Investigator Assessed1.26.7
Partial Response (PR) - Investigator Assessed36.038.0
SecondaryClinical Benefit Rate (CBR)

Clinical Benefit Rate is based upon Independent Review Facility (IRF) assessments; defined as the percentage of participants a complete response (CR), partial response (PR), or stable disease for at least 8 cycles or 6 months.

Time frame:
Tumor assessments every 9 weeks from randomization until Week 27, then every 12 weeks thereafter, until IRF-determined PD, initiation of alternative anticancer medication, or death (up to 5.5 years).
Reported as:
Number · Percentage of participants
Clinical Benefit Rate (CBR)
Percentage of participantsA: Capecitabine + TrastuzumabB: Capecitabine + Trastuzumab + Pertuzumab
Clinical Benefit Rate (CBR)54.0 (47.3 to 60.7)63.6 (57.0 to 69.8)
SecondaryDuration of Objective Response

Duration of Objective Response was defined for the subpopulation of responders as time from first Independent Review Facility (IRF)-assessed complete response (CR) or partial response (PR) to subsequent first documented, IRF-confirmed evidence of disease progression. Only participants with an objective response were included in the analysis of duration of objective response.

Time frame:
Tumor assessments every 9 weeks from randomization until Week 27, then every 12 weeks thereafter, until IRF-determined PD, initiation of alternative anticancer medication, or death (up to 5.5 years).
Reported as:
Median · Weeks
Duration of Objective Response
WeeksA: Capecitabine + TrastuzumabB: Capecitabine + Trastuzumab + Pertuzumab
Duration of Objective Response30.0 (21 to 42)51.6 (42 to 57)

Adverse events

Collected over Adverse events were recorded and reported during the study and up to two years after the last dose of the study drug was received.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
A: Capecitabine + Trastuzumab136/218 (62.4%)53/218 (24.3%)209/218 (95.9%)
B: Capecitabine + Trastuzumab + Pertuzumab134/228 (58.8%)58/228 (25.4%)216/228 (94.7%)
Most frequent serious events
Showing 10 of 91
Most frequent serious events
EventA: Capecitabine + TrastuzumabB: Capecitabine + Trastuzumab + Pertuzumab
Left Ventricular DysfunctionCardiac disorders4/21813/228
DiarrhoeaGastrointestinal disorders6/2188/228
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders4/2183/228
NauseaGastrointestinal disorders2/2181/228
VomitingGastrointestinal disorders2/2181/228
Femur FractureInjury, poisoning and procedural complications2/2182/228
SepsisInfections and infestations2/2180/228
SyncopeNervous system disorders2/2181/228
General Physical Health DeteriorationGeneral disorders2/2182/228
PyrexiaGeneral disorders2/2182/228
Most frequent other events
Showing 10 of 50
Most frequent other events
EventA: Capecitabine + TrastuzumabB: Capecitabine + Trastuzumab + Pertuzumab
Palmar-Plantar Erythrodysaesthesia SyndromeSkin and subcutaneous tissue disorders159/218129/228
DiarrhoeaGastrointestinal disorders128/218157/228
NauseaGastrointestinal disorders97/21888/228
AstheniaGeneral disorders51/21847/228
VomitingGastrointestinal disorders45/21837/228
FatigueGeneral disorders39/21844/228
StomatitisGastrointestinal disorders32/21841/228
HeadacheNervous system disorders39/21840/228
NeutropeniaBlood and lymphatic system disorders38/21829/228
Decreased AppetiteMetabolism and nutrition disorders28/21836/228

Baseline characteristics

This is the safety population, which includes all participants who received any amount of study drug; 6 participants randomized to the Capecitabine + Trastuzumab arm withdrew before receiving any study treatment.

Age, Continuous
Age, Continuous(years)A: Capecitabine + TrastuzumabB: Capecitabine + Trastuzumab + PertuzumabTotal
Mean55.1 ± 10.1053.0 ± 11.2154.0 ± 10.72
Sex: Female, Male
Sex: Female, Male(Participants)A: Capecitabine + TrastuzumabB: Capecitabine + Trastuzumab + PertuzumabTotal
Female218228446
Male000
Region of Enrollment
Region of Enrollment(participants)A: Capecitabine + TrastuzumabB: Capecitabine + Trastuzumab + PertuzumabTotal
Russian Federation8311
Argentina347
Romania6814
Hungary132942
Hong Kong51116
United Kingdom181735
Thailand055
Spain393170
Canada369
Czech Republic121022
Austria235
Netherlands022
Belgium121123
Poland6612
Brazil7613
Korea, Republic of142438
Italy161834
Mexico101
France191231
Peru7815
Germany231134
Croatia437
08

Study locations

190 sites
  • Fundación Investigar
    Buenos Aires, 1025, Argentina
  • Hospital Britanico; Oncologia
    Buenos Aires, C1280AEB, Argentina
  • Instituto FIDES
    La Plata, B1900BAJ, Argentina
  • Instituto de Investigaciones Clínicas Quilmes
    Quilmes, 1878, Argentina
  • Instituto de Oncología de Rosario
    Rosario, S2000KZE, Argentina
  • ISIS Clinica Especializada
    Santa Fe, 03000, Argentina
  • A.Ö. Landesschwerpunktkrankenhaus Krems; Abtl. F. Innere Med.
    Krems, 3500, Austria
  • Landeskrankenhaus Rankweil; Interne E
    Rankweil, 6830, Austria
  • Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt.
    Salzburg, 5020, Austria
  • Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie
    Wien, 1090, Austria
  • Imeldaziekenhuis
    Bonheiden, 2820, Belgium
  • AZ KLINA
    Brasschaat, 2930, Belgium
  • UZ Brussel
    Brussel, 1090, Belgium
  • GHdC Site Notre Dame
    Charleroi, 6000, Belgium
  • CH Jolimont - Lobbes (Jolimont)
    Haine-Saint-Paul, 7100, Belgium
  • Jessa Zkh (Campus Virga Jesse)
    Hasselt, 3500, Belgium
  • AZ Groeninge
    Kortrijk, 8500, Belgium
  • CHU Sart-Tilman
    Liège, 4000, Belgium
  • Clinique Saint-Joseph
    Liège, 4000, Belgium
  • Clinique Ste-Elisabeth
    Namur, 5000, Belgium
  • AZ Nikolaas (Lodewijk)
    Sint-Niklaas, 9100, Belgium
  • Oncologia Sul Capixaba Servicos Medicos - Oncosul
    Cachoeiro Do Itapemirim, ES 29308-014, Brazil
  • Hospital Sao Lucas - PUCRS
    Porto Alegre, RS 90610-000, Brazil
  • Hospital Perola Byington
    Sao Paulo, SP 01317-000, Brazil
  • Hospital A. C. Camargo; Oncologia
    Sao Paulo, SP 01509-010, Brazil
  • Centro Oncológico de Mogi das Cruzes
    São Paulo- SP, SP 08730-500, Brazil
  • Durham Regional Cancer Centre
    Oshawa, Ontario L1G 2B9, Canada
  • Humber River Hospital
    Toronto, Ontario M3M 0B2, Canada
  • University Health Network; Princess Margaret Hospital; Medical Oncology Dept
    Toronto, Ontario M5G 2M9, Canada
  • Uni Hospital For Tumours; Dept of Medical Oncology
    Zagreb, 10000, Croatia
  • Masarykuv onkologicky ustav; Oncology II
    Brno, 656 53, Czechia
  • University Hospital; Oncology and Radiotherapy
    Hradec Kralove, 500 05, Czechia
  • Fakultni Poliklinika Vseobecne Fakultni Niemocnice; Onkologicka Klinika
    Praha 2, 128 08, Czechia
  • Lekarske Fakulty Univerzity Karlovy Fakultni Nemocnice Na Bulovce; Ustav Radiacni Onkologie
    Praha, 180 81, Czechia
  • North Estonia Medical Centre Foundation; Oncology Centre
    Tallinn, 13419, Estonia
  • Tartu University Hospital; Clinic of Hematology and Oncology
    Tartu, 50406, Estonia
  • C.H. Du Pays D'aix En Provence Service du Dr Blanc
    Aix En Provence, 13616, France
  • Centre Oncologie Du Pays Basque
    Bayonne, 64100, France
  • Centre Hospitalier Fleyriat; Oncologie/Hematologie
    Bourg En Bresse, 01012, France
  • CHU Henri Mondor; Service d'Oncologie Medicale
    Creteil, 94010, France
  • Centre Georges Francois Leclerc; Oncologie 3
    Dijon, 21079, France
  • Centre Leon Berard; Oncologie Genetique
    Lyon, 69373, France
  • Centre Antoine Lacassagne; Hopital De Jour A2
    Nice, 06189, France
  • Institut Curie; Oncologie Medicale
    Paris, 75231, France
  • Hopital Saint Antoine; Sce Oncologie
    Paris, 75571, France
  • Institut Jean Godinot; Oncologie Medicale
    Reims CEDEX, 51056, France
  • Centre Henri Becquerel; Oncologie Medicale
    Rouen, 76038, France
  • Centre Rene Huguenin; CONSULT SPECIALISEES
    St Cloud, 92210, France
  • Hopital Hautepierre; Hematologie Oncologie
    Strasbourg, 67098, France
  • Institut Claudius Regaud; Departement Oncologie Medicale
    Toulouse, 31059, France
  • Clinique Pasteur; Oncologie Medicale
    Toulouse, 31076, France
  • CAMPUS CHARITÉ MITTE; Tagesklinik für Onkologie u.Hämatologie
    Berlin, 10117, Germany
  • Klinikum Bremen-Mitte gGmbH; Frauenklinik
    Bremen, 28177, Germany
  • Klinikum Sindelfinden Boblingen
    Böblingen, 71032, Germany
  • Klinikum Darmstadt GmbH; Med. Klinik V; Onkologie & Hämatologie
    Darmstadt, 64283, Germany
  • Klinikum Dortmund gGmbH Klinikzentrum Mitte
    Dortmund, 44137, Germany
  • Universitätsklinikum Essen; Zentrum Für Frauenheilkunde
    Essen, 45122, Germany
  • Klinikum Frankfurt Höchst GmbH; Klinik für Gynäkologie und Geburtshilfe
    Frankfurt, 65929, Germany
  • Klinik Fulda, Medizinisches Versorgungszentrum Osthessen GmbH
    Fulda, 36043, Germany
  • Universitätsklinikum Hamburg-Eppendorf; Zentrum für operative Medizin Klinik für Gynäkologie
    Hamburg, 20246, Germany
  • HOPA MVZ GmbH
    Hamburg, 22767, Germany
  • Diakovere Henriettenstift, Frauenklinik
    Hannover, 30559, Germany
  • Medizinische Hochschule Zentrum Frauenheilkunde Abt.Gynäkologische Onkologie
    Hannover, 30625, Germany
  • ViDia Christliche Kliniken Karlsruhe, Vincentius-Diakonissen-Kliniken gAG; Frauenklinik
    Karlsruhe, 76135, Germany
  • Systemedic Frauenarzte Pruener Gang
    Kiel, 24103, Germany
  • Institut für Versorgungsforschung in der Onkologie GbR Koblenz
    Koblenz, 56068, Germany
  • St. Elisabeth Krankenhaus Köln GmbH; Gynäkologie und Geburtshilfe
    Koeln, 50935, Germany
  • Universitätsklinikum Schleswig-Holstein / Campus Lübeck; Klinik für Frauenheilkunde und Geburtshilfe
    Lübeck, 23538, Germany
  • St. Vincenz-Elisabeth-Hospital; Katholisches Klinikum Mainz
    Mainz, 55131, Germany
  • Klinikum rechts der Isar der TU München; Frauenklinik & Poliklinik
    München, 81675, Germany
  • Universitätsklinikum Münster; Klinik für Frauenheilkunde und Geburtshilfe
    Münster, 48149, Germany
  • St. Josefs Klinik; Medizinische Klinik
    Offenburg, 77654, Germany
  • Praxis für Onkologie und Hämatologie
    Recklinghausen, 45657, Germany
  • Johanniter Klinik
    Stendal, 39576, Germany
  • Klinikum Mutterhaus der Borromaeerinnen gGmbH; Haematologie/Onkologie
    Trier, 54290, Germany
  • GRN Klinik Weinheim
    Weinheim, 69469, Germany
  • Queen Mary Hospital; Surgery
    Hong Kong, 852, Hong Kong
  • Queen Elizabeth Hospital; Clinical Oncology
    Hong Kong, Hong Kong
  • Tuen Mun Hospital; Clinical Oncology
    Hong Kong, Hong Kong
  • Ogyi, Orszagos Gyogyszereszeti Intezet
    Budapest, 1051, Hungary
  • Semmelweis Egyetem Onkologiai Központ
    Budapest, 1083, Hungary
  • Fövárosi Önkormányzat Bajcsy-Zsilinszky Kórház; Onkológiai Osztály
    Budapest, 1106, Hungary
  • Orszagos Onkologiai Intezet; B Belgyogyaszati Osztaly
    Budapest, 1122, Hungary
  • Semmelweis Egyetem Aok; Iii.Sz. Belgyogyaszati Klinika
    Budapest, 1125, Hungary
  • Municipal Hospital of Uzsoki Utca; Centre of Oncoradiology
    Budapest, 1145, Hungary
  • Hospital of Aladar Petz; Dept of Oncoradiology
    Gyor, 9023, Hungary
  • Békés Megyei Pándy Kálmán Kórház; Onkologiai tanszek
    Gyula, 5703, Hungary
  • Kaposi Mor County Hospital; Dept. of Oncology
    Kaposvar, 7400, Hungary
  • Borsod-Abauj-Zemplen Megyei Korhaz Es Egyetemi Oktato Korhaz; Onkologiai Osztaly
    Miskolc, 3501, Hungary
  • Josa Andras Korhaz; Dept of Oncoradiology
    Nyíregyháza, 4400, Hungary
  • Pécsi Tudományegyetem Áok; Onkoterapias Intezet
    Pecs, 7624, Hungary
  • Szegedi Tudomanyegyetem, AOK, Szent-Gyorgyi Albert Klinikai Kozpont, Onkoterapias Klinika
    Szeged, 6720, Hungary
  • Fejér Megyei Szent György Kórház; Onkológiai Osztály
    Szekesfehervar, 8000, Hungary
  • Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház; Onkológiai Osztály
    Szolnok, 5004, Hungary
  • Istituto Tumori Fondazione Pascale; Endocrinologia Oncologica
    Napoli, Campania 80131, Italy
  • Az. Osp. S. Orsola Malpighi; Istituto Di Oncologia Seragnoli
    Bologna, Emilia-Romagna 40138, Italy
  • Ospedale Cervesi di Cattolica ; Unità Operativa di Oncologia ed Oncoematologia
    Cattalica, Emilia-Romagna 47841, Italy
  • AUSL Cesena; Servizio di Oncologia
    Cesena, Emilia-Romagna 47521, Italy
  • Ausl Ravenna-Osp.Infermi; Day Hospital Oncologia Medica
    Faenza, Emilia-Romagna 48018, Italy
  • Ospedale Umberto I ASL di Ravenna Presidio Ospedaliero di Lugo
    Lugo, Emilia-Romagna, Italy

Showing the first 100 of 190 sites across 23 countries. Choose a country and city above to see the rest.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2010 to primary completion in May 2015, 64 months.

Results were first posted in Oct 2016, 1 year 4 months after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 64 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2009
First posted
Dec 4, 2009
StartActual
Jan 26, 2010
Primary completionActual
May 29, 2015
CompletionActual
Aug 7, 2017
Results first posted
Oct 13, 2016
Last update
Aug 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01026142
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 4, 2009
Start date
Jan 26, 2010
Primary completion
May 29, 2015
Completion
Aug 7, 2017
Results posted
Oct 13, 2016
Last update
Aug 14, 2018

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pertuzumab

Start the discussion